Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.

Blood cancer discovery·2026
Same author

Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States.

Blood neoplasia·2025
Same author

A comparative assessment of molecular-based prognostic models in CMML.

Blood neoplasia·2025
Same author

Myeloablative and Reduced Intensity Allogeneic Transplant in Patients with Myeloproliferative Neoplasms.

Hematology/oncology and stem cell therapy·2025
Same author

Asciminib in late-line CML treatment.

Blood advances·2025
Same author

Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia.

American journal of hematology·2025

Related Experiment Video

Updated: Jul 31, 2025

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
08:01

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow

Published on: November 4, 2016

12.4K

Blastic Plasmacytoid Dendritic Cell Neoplasm.

Akriti Jain1, Kendra Sweet2

  • 1University of South Florida, Morsani College of Medicine, Tampa, Florida.

Journal of the National Comprehensive Cancer Network : JNCCN
|May 8, 2023
PubMed
Summary

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare cancer. Tagraxofusp is the first approved targeted therapy, showing high response rates but requiring monitoring for side effects.

Keywords:
BPDCNBlastic Plasmacytoid Dendritic Cell NeoplasmDendritic Cell Neoplasm

More Related Videos

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
13:34

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors

Published on: March 17, 2014

11.3K
Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro
06:12

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro

Published on: March 7, 2022

3.5K

Related Experiment Videos

Last Updated: Jul 31, 2025

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
08:01

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow

Published on: November 4, 2016

12.4K
Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
13:34

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors

Published on: March 17, 2014

11.3K
Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro
06:12

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro

Published on: March 7, 2022

3.5K

Area of Science:

  • Hematologic Malignancies
  • Oncology
  • Immunology

Background:

  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy.
  • Characterized by distinct cutaneous lesions, bone marrow involvement, and specific cell surface markers (CD4, CD56, CD123).
  • Traditional chemotherapy offered transient responses and poor survival; allogeneic stem cell transplantation is potentially curative but limited to select patients.

Purpose of the Study:

  • To review the management of BPDCN, focusing on recent therapeutic advancements.
  • To highlight the efficacy and safety of tagraxofusp, the first approved CD123-targeted therapy.
  • To discuss ongoing clinical trials for novel BPDCN treatments.

Main Methods:

  • Review of clinical trial data and literature on BPDCN management.
  • Analysis of the efficacy and adverse events associated with tagraxofusp.
  • Overview of emerging therapies including IMGN632, venetoclax, CAR-T cells, and bispecific antibodies.

Main Results:

  • Tagraxofusp demonstrated a 90% overall response rate in a Phase I/II trial.
  • Capillary leak syndrome is a significant adverse effect requiring monitoring.
  • Several novel therapeutic strategies are under active investigation.

Conclusions:

  • Tagraxofusp represents a significant advancement in BPDCN treatment, offering a targeted approach.
  • Continued research into novel agents and combinations is crucial for improving outcomes in BPDCN.
  • Early diagnosis and monitoring for adverse effects are key to successful BPDCN management.